164 related articles for article (PubMed ID: 38413563)
1. KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC.
Li J; Shi D; Li S; Shi X; Liu Y; Zhang Y; Wang G; Zhang C; Xia T; Piao HL; Liu HX
Cell Death Dis; 2024 Feb; 15(2):175. PubMed ID: 38413563
[TBL] [Abstract][Full Text] [Related]
2. Survival Outcomes and Treatment Patterns in Patients With NFE2L2 and/or KEAP1 Mutation-Positive Advanced Squamous Cell NSCLC Using a Real-World Clinico-Genomic Database.
Wu Y; Yin Y; Crossland V; Vincent S; Paik PK; Lineberry N; Faller DV
Clin Lung Cancer; 2022 Sep; 23(6):487-497. PubMed ID: 35705448
[TBL] [Abstract][Full Text] [Related]
3. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
4. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF
Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer.
Shen X; Zhao Y; Liu G; Zhou HL; Fan J; Zhang L; Li YL; Wang Y; Liang J; Xu ZX
Life Sci; 2020 Sep; 256():117923. PubMed ID: 32522567
[TBL] [Abstract][Full Text] [Related]
6. NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy.
Xu X; Yang Y; Liu X; Cao N; Zhang P; Zhao S; Chen D; Li L; He Y; Dong X; Wang K; Lin H; Mao N; Liu L
Oncologist; 2020 Jun; 25(6):e955-e963. PubMed ID: 32272498
[TBL] [Abstract][Full Text] [Related]
7. To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations.
Cai R; Zhu H; Liu Y; Sha H; Peng W; Yin R; Zhou G; Fang Y
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10027-10040. PubMed ID: 37261523
[TBL] [Abstract][Full Text] [Related]
8. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.
Mok TSK; Lopes G; Cho BC; Kowalski DM; Kasahara K; Wu YL; de Castro G; Turna HZ; Cristescu R; Aurora-Garg D; Loboda A; Lunceford J; Kobie J; Ayers M; Pietanza MC; Piperdi B; Herbst RS
Ann Oncol; 2023 Apr; 34(4):377-388. PubMed ID: 36709038
[TBL] [Abstract][Full Text] [Related]
9. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
10. IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer.
Liao H; Chang X; Gao L; Ye C; Qiao Y; Xie L; Lin J; Cai S; Dong H
J Transl Med; 2023 Nov; 21(1):828. PubMed ID: 37978543
[TBL] [Abstract][Full Text] [Related]
11. E3 ligase TRIM15 facilitates non-small cell lung cancer progression through mediating Keap1-Nrf2 signaling pathway.
Liang M; Wang L; Sun Z; Chen X; Wang H; Qin L; Zhao W; Geng B
Cell Commun Signal; 2022 May; 20(1):62. PubMed ID: 35534896
[TBL] [Abstract][Full Text] [Related]
12. PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC.
Ji L; Zhang R; Chen J; Xue Q; Moghal N; Tsao MS
Sci Rep; 2019 Aug; 9(1):12437. PubMed ID: 31455821
[TBL] [Abstract][Full Text] [Related]
13. FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer.
Liu J; Wei L; Hu N; Wang D; Ni J; Zhang S; Liu H; Lv T; Yin J; Ye M; Song Y
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104103
[TBL] [Abstract][Full Text] [Related]
14. Keap1-Nrf2 Interaction Suppresses Cell Motility in Lung Adenocarcinomas by Targeting the S100P Protein.
Chien MH; Lee WJ; Hsieh FK; Li CF; Cheng TY; Wang MY; Chen JS; Chow JM; Jan YH; Hsiao M; Hua KT; Kuo ML
Clin Cancer Res; 2015 Oct; 21(20):4719-32. PubMed ID: 26078391
[TBL] [Abstract][Full Text] [Related]
15. Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination.
Sun Z; Mai H; Xue C; Fan Z; Li J; Chen H; Huo N; Kang X; Tang C; Fang L; Zhao H; Han Y; Sun C; Peng H; Du Y; Yang J; Du N; Xu X
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040417
[TBL] [Abstract][Full Text] [Related]
16. Morphine-3-glucuronide upregulates PD-L1 expression
Wang K; Wang J; Liu T; Yu W; Dong N; Zhang C; Xia W; Wei F; Yang L; Ren X
Cancer Biol Med; 2021 Feb; 18(1):155-171. PubMed ID: 33628591
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Pathological Characteristics of
Frank R; Scheffler M; Merkelbach-Bruse S; Ihle MA; Kron A; Rauer M; Ueckeroth F; König K; Michels S; Fischer R; Eisert A; Fassunke J; Heydt C; Serke M; Ko YD; Gerigk U; Geist T; Kaminsky B; Heukamp LC; Clement-Ziza M; Büttner R; Wolf J
Clin Cancer Res; 2018 Jul; 24(13):3087-3096. PubMed ID: 29615460
[No Abstract] [Full Text] [Related]
18. Ubiquitin C-terminal hydrolase L1 promotes expression of programmed cell death-ligand 1 in non-small-cell lung cancer cells.
Mao R; Tan X; Xiao Y; Wang X; Wei Z; Wang J; Wang X; Zhou H; Zhang L; Shi Y
Cancer Sci; 2020 Sep; 111(9):3174-3183. PubMed ID: 32539182
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.
Alessi JV; Elkrief A; Ricciuti B; Wang X; Cortellini A; Vaz VR; Lamberti G; Frias RL; Venkatraman D; Fulgenzi CAM; Pecci F; Recondo G; Di Federico A; Barrichello A; Park H; Nishino M; Hambelton GM; Egger JV; Ladanyi M; Digumarthy S; Johnson BE; Christiani DC; Lin X; Gainor JF; Lin JJ; Pinato DJ; Schoenfeld AJ; Awad MM
J Thorac Oncol; 2023 Jun; 18(6):731-743. PubMed ID: 36775193
[TBL] [Abstract][Full Text] [Related]
20. ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation.
Wu Y; Zhang C; Liu X; He Z; Shan B; Zeng Q; Zhao Q; Zhu H; Liao H; Cen X; Xu X; Zhang M; Hou T; Wang Z; Yan H; Yang S; Sun Y; Chen Y; Wu R; Xie T; Chen W; Najafov A; Ying S; Xia H
Nat Commun; 2021 Apr; 12(1):2346. PubMed ID: 33879767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
